The community’s role in accelerating therapies

In our webinar on “Accelerating Therapy Development: The Patient Community Role,” Molly White, Vice President, Medical Communications & Advocacy at Dyne Therapeutics, discusses the many ways in which your efforts, as individuals and family members living with FSHD, have paved the way for biopharmaceutical companies to pursue drug development. They truly cannot do it without you and the decades of hard work advocacy groups like the FSHD Society have done to promote research, build patient registries, volunteer for natural history studies, and more. She also discusses Dyne’s FSHD program and answers your questions.

Molly brings a unique perspective on the impact of the FSHD community’s role in therapy development. She previously served as chief executive officer of Myotonic, an organization dedicated to advancing research and enhancing the quality of life of people living with myotonic dystrophy.